DIAGNOS Launches "BEAT IT IN A BLINK" a Screening Program for the Prevention of Diabetic Retinopathy and Vision Loss in Canada
(firmenpresse) - BROSSARD, QUEBEC, CANADA -- (Marketwire) -- 10/24/12 -- Diagnos Inc. ("DIAGNOS" or "the Corporation") (TSX VENTURE: ADK) leader in healthcare technical services including algorithm development, data analysis, and image processing, announces today the launch of "BEAT IT IN A BLINK", a program for the prevention of Diabetic Retinopathy, an initially asymptomatic disease that can lead to vision loss.
Using its proprietary Computer Assisted Retinal Analysis (CARA) tele-ophthalmology platform, Diagnos will make early detection of diabetic retinopathy more accessible in Canada to individuals with diabetes through a community based screening service offered at an affordable price of $35.00 CDN.
CARA is approved by Health Canada, US Food and Drug Administration, and the (CE) European Union. With the support of the community and local Diabetes Associations, Diagnos is reaching out to diabetic patients sensitizing them to the complications of the disease as well as the solution now being offered, and inviting them to join "BEAT IT IN A BLINK".
"With nearly 3 million diagnosed diabetics in Canada and 350 million around the world, it is imperative to launch services like BEAT IT IN A BLINK in the local communities. Cost of vision lost in 2010 was $3 Trillion according to the AMD Association and the disease has been increasing every year. At Diagnos, we are proud to innovate and bring this service to the community" says Andre Larente, Diagnos' President.
"Consistent with the director of the National Institutes of Health USA, Dr. Francis Collins' recent calls to preventionism, our recent market tests have clearly confirmed the need for a program that can help individuals with diabetes to beat the odds of losing their vision to a disease whose complications can be preventable if caught early. This is very alarming, and "BEAT IT IN A BLINK" is being launched to make prevention accessible to all." said Peter Nowacki, Diagnos Health Vice-President.
About CARA
CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (POC) and comprises: image upload, image enhancement automated pre-screening, grading by a specialist, and referral to a specialist. CARA's image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras. CARA is a cost-effective tool for processing large numbers of images, in real-time and has been issued a licence by Health Canada and FDA for commercialization.
About DIAGNOS
Founded in 1998, DIAGNOS is a publicly traded Canadian corporation with a mission to commercialize technologies combining contextual imaging and traditional data mining thereby improving decision making processes. DIAGNOS offers products, services, and solutions to clients in a variety of fields including natural resources and healthcare.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release.
For further information, please visit our website at or the SEDAR website at .
Contacts:
Andre Larente, President
DIAGNOS Inc.
(450) 678-8882
Louis Morin
Bid Capital Markets
(514) 845-1101
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 24.10.2012 - 16:16 Uhr
Sprache: Deutsch
News-ID 195888
Anzahl Zeichen: 0
contact information:
Town:
BROSSARD, QUEBEC, CANADA
Kategorie:
Software
Diese Pressemitteilung wurde bisher 191 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DIAGNOS Launches "BEAT IT IN A BLINK" a Screening Program for the Prevention of Diabetic Retinopathy and Vision Loss in Canada"
steht unter der journalistisch-redaktionellen Verantwortung von
Diagnos Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
